International Journal of Scientific Advances
ISSN: 2708-7972
Volume: 5 | Issue: 6 | Nov – Dec 2024 Available Online: www.ijscia.com
DOI: 10.51542/ijscia.v5i6.124

Iron Deficiency Anemia in Pre-dialysis and Dialysis CKD Patients: A Comprehensive Review

I Gede Eka Handrean[1*], I Made Mahadinata Putra MN[1] , I Gede Laksmana Pratama Putra[2]

[1]Medical Education Program, Faculty of Medicine, Universitas Mahasaraswati Denpasar
[2]Medical Student, Faculty of Medicine, Universitas Mahasaraswati Denpasar

E-mail: handrean@unmas.ac.id; mahadinata@unmas.ac.id; laksmanapratama76@gmail.com

*Corresponding author details: I Gede Eka handrean; handrean@unmas.ac.id

ABSTRACT
Iron deficiency anemia is a significant complication in chronic kidney disease (CKD), affecting both pre-dialysis and dialysis patients. This comprehensive review examines the pathophysiology, clinical manifestations, diagnostic approaches, and management strategies of iron deficiency anemia in CKD. The review highlights the complex interplay between iron metabolism, inflammation, and erythropoiesis in CKD patients while discussing current treatment guidelines and future therapeutic directions. Understanding these aspects is crucial for optimal patient care and improved outcomes in CKD-associated anemia.

Keywords: iron deficiency anemia; chronic kidney disease; pre-dialysis; dialysis.

INTRODUCTION

Chronic Kidney Disease (CKD) represents a significant global health burden, affecting approximately 10-15% of the adult population worldwide [1]. Recent systematic reviews indicate that the prevalence of CKD continues to rise globally, with significant variations across different regions and populations [2]. Among its numerous complications, anemia stands as one of the most prevalent and impactful, significantly affecting patients' quality of life and clinical outcomes [3].

Iron deficiency anemia particularly emerges as a critical concern in both pre-dialysis and dialysis CKD patients, with prevalence rates ranging from 24% to 85% depending on the disease stage and population studied [4]. The complex pathophysiology of IDA in CKD patients presents unique challenges in both diagnosis and management [5]. While traditional iron deficiency results from absolute iron deficiency, CKD patients often experience a combination of absolute and functional iron deficiency, complicated by the chronic inflammatory state associated with uremia [6,7].

The impact of IDA in CKD extends beyond traditional hematological parameters, significantly influencing cardiovascular outcomes, cognitive function, and overall mortality rates [8]. Current guidelines emphasize the importance of regular monitoring and appropriate management of anemia in CKD patients [9]. Despite these recommendations, achieving optimal iron status remains challenging, particularly in the context of varying individual responses to therapy and the need for ongoing monitoring [10].

DISCUSSION

Pathophysiology of Iron Deficiency Anemia in CKD

- ***Iron Metabolism in CKD***

Iron metabolism in CKD represents a complex interplay of multiple pathophysiological processes that significantly deviate from normal physiological conditions. Under normal circumstances, iron homeostasis is tightly regulated through the coordination of iron absorption, storage, transport, and utilization. The average adult body contains approximately 3-4 grams of iron, with about 2.5 grams incorporated into hemoglobin [11]. The remainder is distributed between storage forms (ferritin and hemosiderin) and functional components (myoglobin and iron-containing enzymes) [12].

The central regulator of iron homeostasis, hepcidin, plays a crucial role in CKD-associated iron disorders. Hepcidin levels are markedly elevated in CKD patients due to reduced renal clearance and increased production stimulated by inflammatory cytokines [12,13]. This elevation leads to the internalization and degradation of ferroportin, the primary iron export protein, resulting in reduced iron absorption from the gastrointestinal tract and decreased iron release from storage sites [14].

The process of iron absorption in CKD patients is significantly impaired at multiple levels. Dietary iron, primarily in the ferric form (Fe3+), must first be

reduced to ferrous iron (Fe2+) By Duodenal Cytochrome B (DCYTB) before it can be transported across the apical membrane of enterocytes by Divalent Metal Transporter 1 (DMT1) [14,15]. In CKD, the expression and function of both DCYTB and DMT1 are decreased, contributing to reduced iron absorption.

Furthermore, CKD patients experience significant iron losses, particularly those undergoing hemodialysis. These losses occur through multiple mechanisms, including blood retention in dialysis circuits, frequent blood sampling, and gastrointestinal bleeding.4,14 It is estimated that hemodialysis patients may lose approximately 1-2 grams of iron annually through these mechanisms [14]. Additionally, regular hemodialysis sessions can lead to the loss of 5-7 mg of iron per session [15].

The inflammatory state characteristic of CKD also significantly impacts iron metabolism [16]. Pro-inflammatory cytokines, particularly interleukin-6 (IL-6), stimulate hepcidin production and directly interfere with erythropoiesis [16,17]. This inflammation-mediated dysfunction contributes to the development of functional iron deficiency, where despite adequate iron stores, there is insufficient iron availability for effective erythropoiesis [17]. The increased levels of inflammatory markers also affect iron transport proteins, with studies showing altered levels of transferrin and increased levels of ferritin as acute-phase reactants [18].

Oxidative stress, which is markedly increased in CKD patients, further complicates iron metabolism [19]. Enhanced oxidative stress leads to lipid peroxidation and cellular damage, potentially affecting iron transport and utilization [19,20]. The interaction between oxidative stress and iron metabolism creates a vicious cycle, as excess free iron can catalyze the formation of reactive oxygen species through the Fenton reaction [20]. This oxidative stress can further damage erythrocyte membranes and contribute to reduced erythrocyte survival [16]. The dysregulation of iron metabolism in CKD is further complicated by the reduced production of erythropoietin (EPO) [21]. The kidney's decreased ability to produce adequate EPO leads to a relative EPO deficiency, which compounds the problems of iron availability and utilization [21,22]. This creates a complex pathophysiological environment where both iron availability and EPO deficiency contribute to the development of anemia [22,23].

- ***Role of Hepcidin***

Hepcidin, a 25-amino acid peptide hormone primarily synthesized by hepatocytes, emerges as a master regulator of systemic iron homeostasis in CKD [16,17]. In CKD patients, hepcidin levels are pathologically elevated due to multiple factors, creating a complex cascade that significantly impacts iron metabolism [16]. The discovery of hepcidin and its role in iron metabolism has revolutionized our understanding of iron disorders in CKD, providing new insights into the pathogenesis of renal anemia [21].

The regulation of hepcidin expression in CKD involves multiple pathways and factors. One significant pathway is inflammatory regulation. The inflammatory state in CKD leads to increased production of IL-6, which is a potent inducer of hepcidin transcription [16,17]. IL-6 activates the JAK-STAT3 signaling pathway, leading to increased hepcidin expression through direct binding of STAT3 to the hepcidin promoter [24]. Other inflammatory cytokines, including IL-1β and TNF-α, can also contribute to increased hepcidin production, although their effects are less pronounced than those of IL-6 [25].

Another important aspect is iron status-related regulation. The bone morphogenetic protein (BMP) pathway, particularly BMP6, plays a crucial role in the iron-dependent regulation of hepcidin. Transferrin saturation levels influence hepcidin expression through the hemojuvelin/BMP/SMAD pathway. Mutations in proteins involved in this pathway can lead to dysregulation of hepcidin expression [26,27].

Additionally, erythropoiesis-related regulation is significant, where erythroferrone, produced by erythroblasts in response to erythropoietin, acts as a physiological suppressor of hepcidin. In CKD, reduced erythropoietin production and resistance to its actions can lead to decreased erythroferrone, contributing to elevated hepcidin levels [3,28].

Hepcidin dysregulation has significant clinical implications, particularly concerning iron homeostasis and therapeutic strategies. It leads to reduced intestinal iron absorption and decreased release of iron from storage sites, resulting in impaired availability of iron for erythropoiesis [29,30]. This dysregulation can complicate the response to iron therapy and contribute to resistance to erythropoiesis-stimulating agents (ESA). Consequently, understanding hepcidin's role opens avenues for novel therapeutic targeting to improve iron management in affected patients [31,32].

The molecular mechanisms of hepcidin action are complex and multifaceted. Hepcidin binds to ferroportin at a specific site, triggering conformational changes. This binding leads to the ubiquitination of ferroportin and its subsequent internalization, with the internalized ferroportin-hepcidin complex being degraded in lysosomes [29,30]. The cellular effects of hepcidin are notable: in enterocytes, it reduces iron absorption from the gastrointestinal tract by decreasing iron export capacity; in macrophages, it leads to iron retention, affecting iron recycling from senescent erythrocytes; and in hepatocytes, it reduces iron release from storage, affecting systemic iron availability [30,31].

The clinical implications of hepcidin in CKD are significant across diagnostic, therapeutic, and monitoring domains. Diagnostic Value: Hepcidin levels have been shown to correlate with the severity of anemia in CKD, serving as a valuable predictor of patient response to iron therapy and ESA treatment.

Additionally, measuring hepcidin can help identify patients at risk of ESA resistance, thereby guiding clinical decisions [31,32]. Therapeutic Implications: The development of hepcidin antagonists presents a promising avenue for therapeutic intervention, while anti-IL-6 strategies aim to reduce hepcidin production, potentially improving anemia management. Furthermore, novel approaches targeting the bone morphogenetic protein (BMP) pathway are being explored to enhance treatment efficacy [32,33]. Monitoring Considerations: Hepcidin levels may also serve as a guide for initiating iron therapy and determining the optimal timing for iron supplementation, thus improving patient outcomes. Moreover, monitoring hepcidin could play a crucial role in predicting responses to various therapeutic interventions, allowing for more personalized treatment strategies in CKD patients [34].

- ***Absolute vs. Functional Iron Deficiency***

Iron deficiency in CKD patients manifests in two distinct but often overlapping forms, each requiring specific diagnostic and therapeutic approaches [32,35]. Understanding the differences between these conditions is crucial for appropriate clinical management.

Absolute iron deficiency in CKD is characterized by a true depletion of body iron stores, which is evidenced by severely reduced or absent iron in the bone marrow. In non-dialysis CKD patients, a serum ferritin level of less than 100 ng/mL indicates iron deficiency, while in dialysis patients, this threshold is set at less than 200 ng/mL. Additionally, transferrin saturation (TSAT) levels below 20% further confirm the deficiency [35,36].

The primary causes of absolute iron deficiency in CKD can be categorized into two main areas: blood loss and reduced iron intake. Blood losses may occur due to frequent blood sampling, residual blood in dialysis circuits, gastrointestinal bleeding, or surgical procedures. On the other hand, reduced iron intake can result from dietary restrictions, poor appetite, and impaired intestinal absorption, all of which contribute to the overall depletion of iron necessary for maintaining adequate hemoglobin levels and preventing anemia in CKD patients [36,37].

Functional iron deficiency in CKD is defined by the presence of adequate or even elevated iron stores, yet with impaired availability of iron for erythropoiesis. This condition is characterized by normal or elevated serum ferritin levels, typically greater than 100-200 ng/mL, alongside low transferrin saturation levels of less than 20%. Additionally, an increased soluble transferrin receptor is often observed, indicating a disruption in iron utilization [38,39].

The pathophysiological mechanisms underlying functional iron deficiency involve several primary factors, including hepcidin-mediated iron sequestration, interference from inflammatory cytokines, altered iron trafficking, and impaired iron utilization [39,40].

Contributing elements such as chronic inflammation, oxidative stress, uremic toxins, and the increased iron demands associated with ESA therapy further exacerbate this condition. Together, these factors highlight the complex interplay between iron metabolism and the inflammatory state commonly seen in CKD, complicating the management of anemia in affected patients [40,41].

The clinical implications and diagnostic challenges of iron deficiency in CKD are multifaceted, particularly in the context of differential diagnosis. There is often an overlap of laboratory parameters, which complicates the identification of the specific type of iron deficiency. Inflammation can significantly influence biomarkers, necessitating the assessment of multiple markers to achieve an accurate diagnosis. Additionally, time-dependent variations in these parameters can further obscure the clinical picture [42,43].

Treatment considerations are equally complex, as different therapeutic approaches are required based on the type of iron deficiency, and patients may exhibit variable responses to iron supplementation. This underscores the need for individualized treatment strategies tailored to each patient's unique circumstances, along with rigorous monitoring requirements to ensure efficacy and safety [44]. Prognostic implications are also critical, as the type of iron deficiency can impact responsiveness to ESA, influence cardiovascular outcomes, and ultimately affect patient survival and quality of life. Addressing these challenges is essential for optimizing the management of anemia in CKD patients and improving their overall health outcomes [44,45].

Modern diagnostic approaches to iron deficiency in CKD encompass a range of traditional markers, novel biomarkers, and emerging technologies. Traditional markers such as serum ferritin, transferrin saturation, complete blood count, and reticulocyte parameters have long been utilized to assess iron status and anemia [20]. However, advancements in understanding iron metabolism have led to the identification of novel biomarkers that provide deeper insights into iron deficiency. These include hepcidin levels, soluble transferrin receptor, reticulocyte hemoglobin content, percentage of hypochromic red cells, and the zinc protoporphyrin/heme (ZnPP/Heme) ratio, all of which can enhance diagnostic accuracy [20,46].

Furthermore, emerging technologies are revolutionizing the diagnostic landscape, with innovations such as magnetic resonance imaging for assessing tissue iron levels, novel point-of-care testing methods, genetic markers that may influence iron metabolism, and proteomics-based approaches that analyze protein expression related to iron homeostasis.

Together, these modern diagnostic strategies offer a comprehensive framework for accurately diagnosing and managing iron deficiency in CKD, ultimately leading to improved patient outcomes [46,47].

- ***Impact of Inflammation***

Inflammation plays a pivotal role in the pathogenesis of anemia in CKD, creating a complex interplay between immune system activation, iron metabolism, and erythropoiesis [15,32]. The chronic inflammatory state characteristic of CKD contributes significantly to both the development and persistence of anemia through multiple mechanisms [44,48].

Pro-inflammatory cytokines play a crucial role in the pathophysiology of iron deficiency and anemia in CKD, significantly impacting hepcidin expression and erythropoiesis. IL-6 is a primary mediator of hepcidin expression, leading to direct suppression of erythropoiesis and alterations in iron trafficking pathways, which hinder the availability of iron for red blood cell production. Tumor Necrosis Factor-α (TNF-α) further exacerbates this situation by inhibiting the proliferation of erythroid progenitors, enhancing erythrocyte apoptosis, and suppressing EPO production, all of which contribute to anemia. Additionally, Interleukin-1β (IL-1β) enhances hepcidin expression, interferes with iron metabolism, and reduces the expression of EPO receptors, further complicating the body's ability to produce adequate red blood cells. Collectively, these inflammatory mediators create a challenging environment for maintaining normal erythropoiesis and iron homeostasis in CKD patients, highlighting the need for targeted therapeutic strategies to mitigate their effects [48,49].

Acute phase proteins, such as ferritin and C-reactive protein (CRP), significantly influence the interpretation of iron status and the severity of anemia in CKD. Ferritin is synthesized in increased amounts during inflammation, independent of actual iron stores, which complicates the assessment of true iron deficiency and may mask underlying iron depletion. This can lead to misdiagnosis and inappropriate treatment strategies.

CRP serves as a marker of inflammation severity and has been shown to correlate with the severity of anemia, providing insights into the inflammatory state of the patient. Elevated CRP levels can also predict resistance to ESA, complicating anemia management. Additionally, oxidative stress plays a detrimental role in CKD by generating reactive oxygen species, which contribute to increased lipid peroxidation, reduced erythrocyte survival, and impaired erythropoiesis. The interplay between these acute phase proteins and oxidative stress highlights the complex challenges in diagnosing and managing anemia in CKD, necessitating a comprehensive approach to treatment that addresses both iron metabolism and inflammation [49,50].

The mechanisms by which inflammation impacts erythropoiesis and iron metabolism in CKD are multifaceted and significant. Direct effects on erythropoiesis include the suppression of erythroid progenitor cells, which diminishes the production of red blood cells. Inflammatory mediators also reduce the sensitivity of these progenitor cells to EPO, leading to inadequate erythropoiesis. Additionally, inflammation can increase the destruction of erythrocytes and alter iron utilization, further exacerbating anemia [51,52]. Concurrently, inflammation disrupts iron metabolism through several pathways. Enhanced production of hepcidin, a key regulator of iron homeostasis, leads to iron sequestration in macrophages, effectively trapping iron and making it unavailable for erythropoiesis. This process is compounded by reduced iron absorption from the diet and impaired recycling of iron from senescent red blood cells. Together, these mechanisms illustrate how inflammation not only hinders the production of red blood cells but also disrupts the delicate balance of iron metabolism, posing significant challenges in the management of anemia in CKD patients [52,53].



FIGURE 1: Mechanisms of Iron Deficiency Anemia in CKD.

• ***Clinical Manifestations and Diagnosis***

The clinical presentation and diagnostic approach to iron deficiency anemia in CKD patients require comprehensive assessment, as manifestations can be subtle and often overlap with uremic symptoms [4,35].

TABLE 1: The Clinical Manifestations.

Category	Symptoms
A. General Symptoms[35,36].	
Fatigue and Weakness	Reduced physical capacity Exercise intolerance Decreased daily activities
Cognitive Changes	Impaired concentration Memory difficulties Mental fatigue
Constitutional Symptoms	Decreased appetite Poor sleep quality Reduced quality of life
B. Cardiovascular Manifestations[54,55].	
Compensatory Mechanisms	Increased cardiac output Tachycardia Enhanced stroke volume
Cardiac Remodeling	Left ventricular hypertrophy Diastolic dysfunction Altered cardiac energetics

TABLE 2: The Diagnostic Approach.

Diagnostic Approach		Parameters
A. Laboratory Parameters.[39,40]		
Traditional Iron Markers	Serum Ferritin	Primary storage iron marker Affected by inflammation Variable cutoff values based on CKD stage: Non-dialysis CKD: < 100 ng/mL indicates absolute iron deficiency Dialysis CKD: < 200 ng/mL indicates absolute iron deficiency
	TSAT	Functional iron availability marker Target range: 20-30% Values < 20% suggest iron deficiency
Complete Blood Count Parameters	Hemoglobin levels Mean corpuscular volume (MCV) Red cell distribution width (RDW) Reticulocyte count	
B. Novel Biomarkers.[20,45]		
Reticulocyte hemoglobin content (CHr) < 29 pg Percentage of hypochromic red cells > 6% Soluble transferrin receptor Hepcidin levels ZnPP/Heme ratio		

• ***Treatment Approaches***

The management of iron deficiency anemia in CKD requires a comprehensive and individualized approach based on multiple factors [4,37].

TABLE 3: The management of iron deficiency anemia in CKD.

Treatment Approach		Details
A. Oral Iron Therapy [35,36].		
Indications		Non-dialysis CKD with mild-moderate iron deficiency Ferritin < 100 ng/mL and TSAT < 20% Patients declining intravenous therapy
Recommended Preparations		Ferrous sulfate: 200 mg 2-3 times/day Ferrous fumarate: 200 mg 2-3 times/day Ferrous gluconate: 300 mg 2-3 times/day
Limitations		Low bioavailability Gastrointestinal side effects Drug interactions Poor compliance
B. Intravenous Iron Therapy [37,38].		
Indications	Iron Sucrose	Dose: 100-200 mg/session Interval: 1-3 times/week Total dose: 1000 mg Maximum single dose: 200 mg
Available Preparations	Ferric Carboxymaltose	Dose: up to 1000 mg/session Interval: minimum 1 week Maximum single dose: 1000 mg
ESA Therapy		
Indications		Hemoglobin < 10 g/dL Adequate iron stores No active inflammation
Dosing Guidelines	Epoetin alfa	Initial: 50-100 IU/kg 3x/week Maintenance: individualized Maximum: 300 IU/kg/week
	Darbepoetin alfa	Initial: 0.45 µg/kg weekly Maintenance: individualized Maximum: 1.5 µg/kg/week

TABLE 4: The Monitoring Requirements and Safety Considerations [40,41].

Monitoring Requirements	Details
A. Iron Status Monitoring	
Pre-dialysis CKD	Hemoglobin: every 3 months Iron studies: every 3-6 months
Hemodialysis	Hemoglobin: monthly Iron studies: every 3 months More frequent during active treatment
B. ESA Therapy Monitoring	
Initial Phase	Weekly hemoglobin checks Blood pressure monitoring Iron status every 4-8 weeks
Maintenance Phase	Monthly hemoglobin Iron status every 3 months Clinical assessment for complications

TABLE 5: The Safety Parameters [41,42].

Safety Parameters	Details
A. Iron Therapy Safety	
Pre-administration Assessment	Vital signs Recent infection history Previous reaction history
During Administration	Vital signs every 15 minutes Allergic reaction monitoring Infusion site observation
B. ESA Safety	
Cardiovascular Monitoring	Blood pressure control Heart failure symptoms Thrombotic events
Target Hemoglobin	Hemoglobin: 10-11.5 g/dL TSAT: 20-30% Serum Ferritin: Non-dialysis CKD: 200-500 ng/mL Dialysis CKD: 200-800 ng/mL

CONCLUSIONS

Iron deficiency anemia remains a significant challenge in the management of CKD patients, with complex pathophysiological mechanisms and substantial clinical implications. This review emphasizes the importance of a comprehensive, individualized approach to managing iron deficiency anemia in CKD patients while highlighting areas for future research and development.

REFERENCES

[1] Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet 2020;395:709–33. https://doi.org/10.1016/S0140-6736(20)30045-3.

[2] Hill NR, Fatoba ST, Oke JL, Hirst JA, O'Callaghan CA, Lasserson DS, et al. Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. PLoS One 2016;11:e0158765. https://doi.org/10.1371/journal.pone.0158765.

[3] Babitt JL, Lin HY. Mechanisms of Anemia in CKD. Journal of the American Society of Nephrology 2012;23:1631–4. https://doi.org/10.1681/ASN.2011111078.

[4] Fishbane S, Spinowitz B. Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018. American Journal of Kidney Diseases 2018;71:423–35. https://doi.org/10.1053/j.ajkd.2017.09.026.

[5] Cappellini MD, Comin-Colet J, de Francisco A, Dignass A, Doehner W, Lam CS, et al. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am J Hematol 2017;92:1068–78. https://doi.org/10.1002/ajh.24820.

[6] McMurray JJV, PPS, AJW, AP, BJS, BJ, DTB, FFO, FS, GT, MIC, MRA, MLP, OGT, SGFM, WG, & WA. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl (2011) 2012;2:279. https://doi.org/10.1038/kisup.2012.37.

[7] Wong MMY, Tu C, Li Y, Perlman RL, Pecoits-Filho R, Lopes AA, et al. Anemia and iron deficiency among chronic kidney disease Stages 3–5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated. Clin Kidney J 2020;13:613–24. https://doi.org/10.1093/ckj/sfz091.

[8] Mikhail A, Brown C, Williams JA, Mathrani V, Shrivastava R, Evans J, et al. Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC Nephrol 2017;18:345. https://doi.org/10.1186/s12882-017-0688-1.

[9] Wish JB. Assessing Iron Status. Clinical Journal of the American Society of Nephrology 2006;1:S4–8. https://doi.org/10.2215/CJN.01490506.

[10] Bresgen N, Eckl P. Oxidative Stress and the Homeodynamics of Iron Metabolism. Biomolecules 2015;5:808–47. https://doi.org/10.3390/biom5020808.

[11] Ganz T. Systemic Iron Homeostasis. Physiol Rev 2013;93:1721–41. https://doi.org/10.1152/physrev.00008.2013.

[12] Tsuchiya K, Nitta K. Hepcidin is a Potential Regulator of Iron Status in Chronic Kidney Disease. Therapeutic Apheresis and Dialysis 2013;17:1–8. https://doi.org/10.1111/1744-9987.12001.

[13] Akchurin O, Patino E, Dalal V, Meza K, Bhatia D, Brovender S, et al. Interleukin-6 Contributes to the Development of Anemia in Juvenile CKD. Kidney Int Rep 2019;4:470–83. https://doi.org/10.1016/j.ekir.2018.12.006.

[14] Agarwal AK. Iron metabolism and management: focus on chronic kidney disease. Kidney Int Suppl (2011) 2021;11:46–58. https://doi.org/10.1016/j.kisu.2020.12.003.

[15] Gluba-Brzózka A, Franczyk B, Olszewski R, Rysz J. The Influence of Inflammation on Anemia in CKD Patients. Int J Mol Sci 2020;21:725. https://doi.org/10.3390/ijms21030725.

[16] Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood 2019;133:40–50. https://doi.org/10.1182/blood-2018-06-856500.

[17] Nemeth E, Ganz T. The Role of Hepcidin in Iron Metabolism. Acta Haematol 2009;122:78–86. https://doi.org/10.1159/000243791.

[18] Muckenthaler MU, Rivella S, Hentze MW, Galy B. A Red Carpet for Iron Metabolism. Cell 2017;168:344–61. https://doi.org/10.1016/j.cell.2016.12.034.

[19] Theurl I, Aigner E, Theurl M, Nairz M, Seifert M, Schroll A, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood 2009;113:5277–86. https://doi.org/10.1182/blood-2008-12-195651.

[20] Hain D, Bednarski D, Cahill M, Dix A, Foote B, Haras MS, et al. Iron-Deficiency Anemia in CKD: A Narrative Review for the Kidney Care Team. Kidney Med 2023;5:100677. https://doi.org/10.1016/j.xkme.2023.100677.

[21] Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica 2020;105:260–72. https://doi.org/10.3324/haematol.2019.232124.

[22] Vaziri ND. Oxidative stress in uremia: Nature, mechanisms, and potential consequences. Semin Nephrol 2004;24:469–73. https://doi.org/10.1016/j.semnephrol.2004.06.026.

[23] Pantopoulos K, Porwal SK, Tartakoff A, Devireddy L. Mechanisms of Mammalian Iron Homeostasis. Biochemistry 2012;51:5705–24. https://doi.org/10.1021/bi300752r.

[24] Nemeth E, Preza GC, Jung C-L, Kaplan J, Waring AJ, Ganz T. The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-function study. Blood 2006;107:328–33. https://doi.org/10.1182/blood-2005-05-2049.

[25] Collins JF, Wessling-Resnick M, Knutson MD. Hepcidin Regulation of Iron Transport. J Nutr 2008;138:2284–8. https://doi.org/10.3945/jn.108.096347.

[26] Ganz T, Nemeth E. The Hepcidin-Ferroportin System as a Therapeutic Target in Anemias and Iron Overload Disorders. Hematology 2011;2011:538–42. https://doi.org/10.1182/asheducation-2011.1.538.

[27] Camaschella C. Iron and hepcidin: a story of recycling and balance. Hematology 2013;2013:1–8. https://doi.org/10.1182/asheducation-2013.1.1.

[28] Kautz L. Erythroferrone: An Erythroid Regulator of Iron Metabolism. Médecine/Sciences 2014;30:834–6. https://doi.org/10.1051/medsci/20143010005.

[29] Ross SL, Tran L, Winters A, Lee K-J, Plewa C, Foltz I, et al. Molecular Mechanism of Hepcidin-Mediated Ferroportin Internalization Requires Ferroportin Lysines, Not Tyrosines or JAK-STAT. Cell Metab 2012;15:905–17. https://doi.org/10.1016/j.cmet.2012.03.017.

[30] Coffey R, Ganz T. Iron homeostasis: An anthropocentric perspective. Journal of Biological Chemistry 2017;292:12727–34. https://doi.org/10.1074/jbc.R117.781823.

[31] van der Weerd NC, Grooteman MPC, Nubé MJ, ter Wee PM, Swinkels DW, Gaillard CAJM. Hepcidin in chronic kidney disease: not an anaemia management tool, but promising as a cardiovascular biomarker. Neth J Med 2015;73:108–18.

[32] Ganz T, Nemeth E. Iron Balance and the Role of Hepcidin in Chronic Kidney Disease. Semin Nephrol 2016;36:87–93. https://doi.org/10.1016/j.semnephrol.2016.02.001.

[33] Haase VH. Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev 2013;27:41–53. https://doi.org/10.1016/j.blre.2012.12.003.

[34] Coyne DW. Hepcidin: clinical utility as a diagnostic tool and therapeutic target. Kidney Int 2011;80:240–4. https://doi.org/10.1038/ki.2011.141.

[35] Roger SD. Practical considerations for iron therapy in the management of anaemia in patients with chronic kidney disease. Clin Kidney J 2017;10:i9–15. https://doi.org/10.1093/ckj/sfx100.

[36] Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. The Lancet 2016;387:907–16. https://doi.org/10.1016/S0140-6736(15)60865-0.

[37] Ratcliffe LEK, Thomas W, Glen J, Padhi S, Pordes BAJ, Wonderling D, et al. Diagnosis and Management of Iron Deficiency in CKD: A Summary of the NICE Guideline Recommendations and Their Rationale. American Journal of Kidney Diseases 2016;67:548–58. https://doi.org/10.1053/j.ajkd.2015.11.012.

[38] Silvestri L, Nai A. Iron and erythropoiesis: A mutual alliance. Semin Hematol 2021;58:145–52. https://doi.org/10.1053/j.seminhematol.2021.05.002.

[39] Bhandari S, Oliveira B, Spencer S, Mikhail A, Brooks O, Bryant G, et al. Clinical Practice Guideline: Anaemia of Chronic Kidney Disease 2024.

[40] Tomasz G, Ewa W, Jolanta M. Biomarkers of iron metabolism in chronic kidney disease. Int Urol Nephrol 2021;53:935–44. https://doi.org/10.1007/s11255-020-02663-z.

[41] Ginzburg YZ. Hepcidin-ferroportin axis in health and disease, 2019, p. 17–45. https://doi.org/10.1016/bs.vh.2019.01.002.

[42] Lanser L, Fuchs D, Kurz K, Weiss G. Physiology and Inflammation Driven Pathophysiology of Iron Homeostasis—Mechanistic Insights into Anemia of Inflammation and Its Treatment. Nutrients 2021;13:3732. https://doi.org/10.3390/nu13113732.

[43] Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, et al. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int 2015;87:162–8. https://doi.org/10.1038/ki.2014.275.

[44] Ueda N, Takasawa K. Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease. Nutrients 2018;10:1173. https://doi.org/10.3390/nu10091173.

[45] Rostoker G, Griuncelli M, Loridon C, Couprie R, Benmaadi A, Bounhiol C, et al. Hemodialysis-associated Hemosiderosis in the Era of Erythropoiesis-stimulating Agents: A MRI Study. Am J Med 2012;125:991-999.e1. https://doi.org/10.1016/j.amjmed.2012.01.015.

[46] Batchelor EK, Kapitsinou P, Pergola PE, Kovesdy CP, Jalal DI. Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment. Journal of the American Society of Nephrology 2020;31:456–68. https://doi.org/10.1681/ASN.2019020213.

[47] Nuhu F, Bhandari S. Oxidative Stress and Cardiovascular Complications in Chronic Kidney Disease, the Impact of Anaemia. Pharmaceuticals 2018;11:103. https://doi.org/10.3390/ph11040103.

[48] Akchurin OM, Kaskel F. Update on Inflammation in Chronic Kidney Disease. Blood Purif 2015;39:84–92. https://doi.org/10.1159/000368940.

[49] Portolés J, Martín L, Broseta JJ, Cases A. Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents. Front Med (Lausanne) 2021;8:642296. https://doi.org/10.3389/fmed.2021.642296.

[50] Ku E, Del Vecchio L, Eckardt K-U, Haase VH, Johansen KL, Nangaku M, et al. Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2023;104:655–80. https://doi.org/10.1016/j.kint.2023.05.009.

[51] Wang B, Li Z-L, Zhang Y-L, Wen Y, Gao Y-M, Liu B-C. Hypoxia and chronic kidney disease. EBioMedicine 2022;77:103942. https://doi.org/10.1016/j.ebiom.2022.103942.

[52] Abba ML, Riabov V, Nowak D, Hofmann W-K, Boch T. Understanding iron homeostasis in MDS: the role of erythroferrone. Front Oncol 2024;14. https://doi.org/10.3389/fonc.2024.1404817.

[53] Locatelli F, Fishbane S, Block GA, Macdougall IC. Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients. Am J Nephrol 2017;45:187–99. https://doi.org/10.1159/000455166.

[54] Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J 2013;34:816–29. https://doi.org/10.1093/eurheartj/ehs224.

[55] Cai A, Wu Z, Xu L, Xia S, He X, Zhang Y, et al. Association of anaemia and all-cause mortality in patients with ischaemic heart failure varies by renal function status. ESC Heart Fail 2021;8:2270–81. https://doi.org/10.1002/ehf2.13325.